Marcaine

Bupivacaine Hydrochloride, the active ingredient in Marcaine, is a local anesthetic (amide) presented as a sterile injectable solution for epidural, infiltration, and intra‑articular use. It provides long‑lasting numbness for labor, minor surgery and joint pain management. GNH USA supplies Marcaine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marcaine (bupivacaine) is a long‑acting amide local anesthetic used for regional pain control.

- Epidural analgesia for labor: provides sustained pain relief during childbirth. - Surgical infiltration anesthesia: produces local numbness for minor surgical procedures. - Intra‑articular injection for joint pain: reduces pain in orthopedic interventions.

Common Side Effects: - Transient numbness or tingling at the injection site. - Mild hypotension. - Bradycardia. - Dizziness. - Nausea. - Headache.

Serious or Rare Side Effects: - Cardiovascular toxicity such as arrhythmia or cardiac arrest. - Central nervous system toxicity including seizures and respiratory depression. - Allergic reactions ranging from rash to anaphylaxis. - Methemoglobinemia (rare).

Before using Marcaine, clinicians should assess patient-specific factors and follow safe administration practices. - Patient assessment: evaluate cardiac and neurological status prior to injection. - Dose limits: adhere to recommended maximum cumulative dose. - Elderly or hepatic impairment: use reduced amounts and monitor closely. - Intravascular injection: aspirate before administration to avoid systemic exposure. - Monitoring: observe for signs of toxicity during and after the procedure. - Store at ambient temperature: keep in original container, protect from light and moisture.

Marcaine may interact with other drugs that affect cardiac conduction or sodium channel function.

Major Interactions (Avoid): - Co‑administration with other local anesthetics or sodium channel blockers (e.g., lidocaine, quinidine) can increase systemic toxicity. - Beta‑adrenergic antagonists (e.g., propranolol) may potentiate cardiotoxic effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole) may raise plasma bupivacaine levels.

Moderate Interactions (Monitor Closely): - General anesthetics (e.g., propofol) may enhance central nervous system depression. - Diuretics can alter plasma protein binding, affecting free drug concentration. - Anticoagulants increase the risk of hematoma after regional block procedures.